Compare DGX & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGX | MDLN |
|---|---|---|
| Founded | 1967 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 30.7B |
| IPO Year | 1996 | 2025 |
| Metric | DGX | MDLN |
|---|---|---|
| Price | $242.34 | $34.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 27 |
| Target Price | ★ $251.40 | $44.42 |
| AVG Volume (30 Days) | 791.2K | ★ 7.6M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 5.08 | 0.23 |
| Revenue | $11,035,000,000.00 | ★ $28,432,000,000.00 |
| Revenue This Year | $8.86 | $9.84 |
| Revenue Next Year | $4.58 | $7.85 |
| P/E Ratio | ★ $47.99 | $151.11 |
| Revenue Growth | ★ 11.78 | 11.47 |
| 52 Week Low | $171.18 | $31.49 |
| 52 Week High | $248.84 | $50.88 |
| Indicator | DGX | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 41.52 |
| Support Level | $228.47 | $32.47 |
| Resistance Level | $248.02 | $37.17 |
| Average True Range (ATR) | 6.41 | 1.05 |
| MACD | 1.31 | -0.16 |
| Stochastic Oscillator | 83.02 | 14.14 |
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.